Your browser doesn't support javascript.
loading
An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.
Cove-Smith, Laura; Woodhouse, Neil; Hargreaves, Adam; Kirk, Jason; Smith, Susan; Price, Sally A; Galvin, Melanie; Betts, Catherine J; Brocklehurst, Simon; Backen, Alison; Radford, John; Linton, Kim; Roberts, Ruth A; Schmitt, Matthias; Dive, Caroline; Tugwood, Jonathan D; Hockings, Paul D; Mellor, Howard R.
Afiliação
  • Cove-Smith L; Clinical & Experimental Pharmacology, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.
  • Woodhouse N; Personalised Healthcare & Biomarkers, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Hargreaves A; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Kirk J; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Smith S; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Price SA; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Galvin M; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Betts CJ; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Brocklehurst S; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Backen A; Clinical & Experimental Pharmacology, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
  • Radford J; University of Manchester, Institute of Cancer Sciences, Oxford Road, Manchester M13 9PT, UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.
  • Linton K; University of Manchester, Institute of Cancer Sciences, Oxford Road, Manchester M13 9PT, UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK.
  • Roberts RA; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK.
  • Schmitt M; North West Regional Heart Centre, University Hospital of South Manchester, Wythenshawe, Manchester M23 9LT, UK.
  • Dive C; Clinical & Experimental Pharmacology, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
  • Tugwood JD; Clinical & Experimental Pharmacology, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
  • Hockings PD; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK MedTech West, Chalmers University of Technology, 41296 Gothenburg, Sweden.
  • Mellor HR; Drug Safety & Metabolism, Innovative Medicines, AstraZeneca R&D, Alderley Park Macclesfield, Cheshire, SK10 4TF, UK howard_mellor@vrtx.com.
Toxicol Sci ; 140(1): 3-15, 2014 Jul.
Article em En | MEDLINE | ID: mdl-24675088

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Troponina I / Antibióticos Antineoplásicos / Cardiomiopatias / Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Troponina I / Antibióticos Antineoplásicos / Cardiomiopatias / Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2014 Tipo de documento: Article